JD

Jakob Dupont

Imugene Limited | Non-Executive Director
Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. Dr Dupont is currently the Global Head of Research and Development at NASDAQ-listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversees all research and development including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs. He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. Prior to Atara, Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche including as Vice President, Global Head of Breast and GYN Cancer Development, in addition to a further five years at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer. Dr Dupont is currently an Independent Director at Apexigen (NASDAQ: APGN) and a Scientific Advisory Board Member at AMBRX (NASDAQ: AMAM). He has been published 48 times in peer-reviewed journals and has established relationships with global clinical and research oncologists, collaborative groups, industry and investors.

Company and Role

Company
Title
Tenure
Since
IMU
Imugene Limited
  • Non-Executive Director
1yrs, 10mthSep 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
IMU
Imugene Limited
01/07/24339,286N/A2,189,286N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
IMU
Imugene Limited
01/07/24
Issued
250,000$0.055$13,750Conversion of securities
IMU
Imugene Limited
01/07/24
Exercise
250,000$0.055$13,750Conversion of securities
IMU
Imugene Limited
12/01/24
Issued
1,000,000$0.120$120,000Issue of securities
IMU
Imugene Limited
03/10/23
Issued
89,286$0.047$4,196Placement
IMU
Imugene Limited
03/10/23
Issued
89,286$0.084$7,500Placement